PA
CBAY

Perceptive Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Perceptive Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,024,400
Closed -$95.1M – 126
2023
Q4 		$95.1M Sell
4,024,400
-18,791
-0.5% -$335K 2.12% 11
2023
Q3 		$60.3M Buy
4,043,191
+309,936
+8% +$4.11M 2.01% 14
2023
Q2 		$40.9M Sell
3,733,255
-170,000
-4% -$1.58M 1.18% 26
2023
Q1 		$34M Buy
3,903,255
+3,194,262
+451% +$25.6M 1% 32
2022
Q4 		$4.45M Buy
+708,993
New +$2.69M 0.12% 72
2019
Q4 		– Sell
-1,520,355
Closed -$7.78M – 124
2019
Q3 		$7.78M Sell
1,520,355
-2,342,466
-61% -$14.2M 0.21% 60
2019
Q2 		$27.7M Sell
3,862,821
-350,000
-8% -$3.96M 0.63% 40
2019
Q1 		$55.9M Buy
4,212,821
+1,750,000
+71% +$18.6M 1.58% 19
2018
Q4 		$19.4M Sell
2,462,821
-280,000
-10% -$2.67M 0.74% 36
2018
Q3 		$30.4M Hold
2,742,821
– – 0.81% 39
2018
Q2 		$36.8M Sell
2,742,821
-60,000
-2% -$751K 0.97% 32
2018
Q1 		$33.7M Buy
2,802,821
+116,939
+4% +$1.45M 0.95% 27
2017
Q4 		$24.7M Buy
2,685,882
+335,000
+14% +$2.86M 0.82% 29
2017
Q3 		$18.9M Buy
+2,350,882
New +$15.9M 0.72% 33

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Perceptive Advisors's CBAY Position: Q1 2024 in Review

Perceptive Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 4,024,400 shares — an estimated $95.1M sold.

Perceptive Advisors first reported a position in CBAY in Q3 2017 and held it in 14 quarters. The position peaked at $95.1M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Perceptive Advisors reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Perceptive Advisors sold 4,024,400 Cymabay Therapeutics shares in Q1 2024, an estimated $95.1M.
  • Perceptive Advisors first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 14 quarters.
  • Perceptive Advisors's Cymabay Therapeutics position peaked at $95.1M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Perceptive Advisors's 13F filing for Q1 2024, filed 15 May 2024.